Low impact
Dr Reddy's rises 2% on HIV-prevention drug approval; Sun Pharma clarifies plant report
Dr Reddy's received tentative US FDA approval for a generic version of lenacapavir, a twice-yearly injection used to prevent HIV, intended for supply to about 120 low- and middle-income countries. Its shares rose 1.96% to ₹1,368.30. BSE asked the company to clarify a media report on the approval. Sun Pharma told exchanges that reports of an order to halt eye-drug production at its Assam plant relate to August events; it says it paused production voluntarily and has filed a compliance report. Its shares were almost flat.
The chain of consequences
- 1US FDA gives tentative approval to Dr Reddy's generic lenacapavir injection
- 2Supply aimed at about 120 lower-income countries from late 2026
- 3Dr Reddy's closes at the day's high
- 4Nifty Pharma rises 0.42%
Tends to gain
Dr Reddy's
Tends to lose
None directly
If it reverses
Tentative approval does not allow US sales because of patents, so near-term revenue depends on export programmes.
Companies in this story
Other stories today
- Foreign investors buy a net ₹6,837 crore, the most in a single day since October 2025
- Brent settles at $103.60 after US strikes on Iran's Qeshm Island, as Qatar keeps talks alive
- US votes in midterm elections; 10-year bond yield rises to about 4.96%
- Consumer goods shares lead as Marico jumps about 10% after results
- Private banks rise 2%, state-run banks fall 1.3% as SBI reports results
- Reports of a capital gains tax review add to buying, but nothing is decided
- Power Grid falls 3%, the weakest Nifty share, as power utilities lag
- Defence shares extend rebound; BEL keeps its 15%-plus growth outlook
- Coal India reported to plan a $1 billion share sale in Mahanadi Coalfields
- Auto shares rise 1.7% for a second day after record October sales
- Apollo Hospitals and NHPC report September-quarter results today